

INFORMAZIONI PERSONALI

Giulia Galli



Sesso Femminile | Data di nascita 25/12/1988 | Nazionalità Italiana

ESPERIENZA PROFESSIONALE

-
- 12/2014–12/2019 Scuola di specializzazione in Oncologia Medica
Fondazione IRCCS Istituto Nazionale dei Tumori di Milano
Dipartimento di Oncologia Medica – unità di Oncologia Toracica
- 02/2014–08/2014 Frequenza volontaria post-laurea
Fondazione IRCCS Istituto Nazionale dei Tumori di Milano
Dipartimento di Oncologia Medica - s.c. Oncologia Medica 1
- 02/2011–07/2013 Internato di tesi
Fondazione IRCCS Istituto Nazionale dei Tumori di Milano
Dipartimento di Oncologia Medica - s.c. Oncologia Medica 1

ISTRUZIONE E FORMAZIONE

-
- 18/12/2019 Specializzazione in Oncologia Medica
Università degli Studi di Milano
Tesi: "Impact of lipid metabolism on outcome of patients with advanced non small cell lung cancer treated with immunotherapy"
Relatore: Prof. Filippo de Braud – Correlatore: Dr.ssa Marina Chiara Garassino
- 10/2018 Avvio di dottorato in Ricerca Clinica
Università degli Studi di Milano
- 04/03/2014 Abilitazione all'esercizio della professione medica
Iscrizione all'albo dei Medici Chirurghi di Varese
- 17/07/2013 Laurea magistrale a ciclo unico in Medicina e Chirurgia Livello 7 QEQ
Università degli Studi di Milano
Tesi: "Lo studio ASTER: esperienza monoistituzionale di trattamento chemioterapico sequenziale per il carcinoma mammario operabile"
Relatore: Prof. Alessandro Massimo Gianni
- 07/2007 Diploma di scuola media superiore Livello 4 QEQ
Liceo Ginnasio Statale S. M. Legnani

COMPETENZE PERSONALI

Lingua madre Italiano

Altre lingue

COMPRESIONE

PARLATO

PRODUZIONE SCRITTA

	Ascolto	Letture	Interazione	Produzione orale	
inglese	C1	C2	C1	C1	B2

Livelli: A1 e A2: Utente base - B1 e B2: Utente autonomo - C1 e C2: Utente avanzato
Quadro Comune Europeo di Riferimento delle Lingue

Patente di guida B

ULTERIORI INFORMAZIONI

Esperienze all'estero ESMO Fellowship - Translational Research Unit visit - General Hospital Vienna (maggio 2019)

Appartenenza ad associazioni Associazione Italiana di Oncologia Medica (AIOM)
 European Society of Medical Oncology (ESMO)
 American Society of Clinical Oncology (ASCO)
 International Association for the Study of Lung Cancer (IASLC)

Certificazioni Attestazione di Good Clinical Practice (GCP)
 Attestazione IELTS Academic di conoscenza della lingua inglese (26/04/2018)

Riconoscimenti e premi ESMO European Lung Cancer Conference (ELCC) Merit Award 2019
 Premio "Miglior presentazione orale" al Congresso Nazionale dell'Associazione Italiana di Oncologia Medica (2016)
 Premio "Supporto a giovani medici volenterosi attivamente coinvolti in progetti per diagnosi e cura di gravi malattie" indetto dalla Fondazione Giancarlo Quarta ONLUS (2014)

Pubblicazioni *in extenso* "EPSiLoN: a prognostic score for immunotherapy in advanced non-small-cell lung cancer: a validation cohort." Prelaj A, Ferrara R, Rebuzzi SE, Proto C, Signorelli D, Galli G, De Toma A, Randon G, Pagani F, Viscardi G, Brambilla M, Trevisan B, Ganzinelli M, Martinetti A, Gallucci R, Di Mauro RM, Molino G, Zilembo N, Torri V, de Braud F, Garassino MC, Lo Russo G. [Accettato per pubblicazione da *Cancers* il 02/11/ 2019]. doi: 10.3390/cancers11121954.

"Multiple sclerosis associated with pembrolizumab in a patient with non-small cell lung cancer". Romeo MAL, Garassino MC, Moiola L, Galli G, Comi G, Martinelli V, Filippi M. *J Neurol* 2019; 266(12):3163-3166. doi: 10.1007/s00415-019-09562-z.

"Efficacy and safety of immunotherapy in elderly patients with non-small cell lung cancer." Galli G, De Toma A, Pagani F, Randon G, Trevisan B, Prelaj A, Ferrara R, Proto C, Signorelli D, Ganzinelli M, Zilembo N, de Braud F, Garassino MC, Lo Russo G. *Lung Cancer* 2019; 137:38-42. doi: 10.1016/j.lungcan.2019.08.030.

"Unusual skin toxicity associated with sustained disease response induced by nivolumab in a patient with non-small cell lung cancer." Galli G, Proto C, Cossa M, Valeri B, Sdao S, Signorelli D, Imbimbo M, de Braud F, Garassino MC, Lo Russo G. [Accettato per pubblicazione da *Tumori J* il 30 luglio 2019]. doi: 10.1177/0300891619872546.

"Weighing the prognostic role of hyponatremia in hospitalized patients with metastatic solid tumors: the HYPNOSIS study." Fucà G, Mariani L, Lo Vullo S, Galli G, Berardi R, Di Nicola M, Vernieri C, Morelli D, Dotti K, Fiordoliva I, Rinaldi S, Gavazzi C, Pietrantonio F, Platania M, de Braud F. *Sci Rep* 2019; 9(1):12993. doi: 10.1038/s41598-019-49601-3.

"Axillary nodal involvement by primary tumor features in early breast cancer: an analysis of 2600 patients." De Santis MC, La Rocca E, Meneghini E, Bregni G, Di Lorenzo G, Galli G, Di Nicola M, Folli S, Gennaro M, Pruneri G, Paolini B, Daidone MG, de Braud F, Apolone G, Sant M, Di Cosimo S. [Accettato per pubblicazione da *Clin Transl Oncol* il 14/07/2019]. doi: 10.1007/s12094-019-02188-7.

"Characterization of patients with metastatic Non Small Cell Lung Cancer obtaining Long Term Benefit from Immunotherapy." Galli G, Proto C, Signorelli D, Imbimbo M, Ferrara R, Prelaj A, De Toma A, Ganzinelli M, Zilembo N, de Braud F, Garassino MC, Lo Russo G. *Front Oncol* 2019; 15(23):2743-2757. doi: 10.2217/fon-2019-0055.

"The prognostic role of TNM staging compared to Tumor volume and Number of Pleural Sites in malignant pleural mesothelioma." Proto C, Signorelli D, Mallone S, Prelaj A, Lo Russo G, Imbimbo M,

Galli G, Ferrara R, Ganzinelli M, Leuzzi G, Greco FG, Calareso G, Botta L, Gatta G, Garassino MC, Trama A. *Clin Lung Can* 2019; 20(6):e652-e660. doi: 10.1016/j.clc.2019.06.019.

"Association between Antibiotic-Immunotherapy Exposure Ratio and outcome in metastatic Non Small Cell Lung Cancer." **Galli G**, Triulzi T, Proto C, Signorelli D, Imbimbo M, Poggi M, Fucà G, Ganzinelli M, Vitali M, Palmieri D, Tessari A, de Braud F, Garassino MC, Colombo MP, Lo Russo G. *Lung Cancer* 2019; 132:72-78. doi: 10.1016/j.lungcan.2019.04.008.

"Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): what to add and what to leave out." Proto C, Ferrara R, Signorelli D, Lo Russo G, **Galli G**, Imbimbo M, Prelaj A, Zilembo N, Ganzinelli M, Pallavicini L, De Simone I, Colombo MP, Sica A, Torri V, Garassino MC. *Cancer Treat Rev* 2019; 75:39-51. doi: 10.1016/j.ctrv.2019.03.004.

"Combination of immunotherapy and brain radiotherapy in metastatic melanoma: a retrospective analysis." **Galli G**, Cavalieri S, Di Guardo LA, Cimminiello C, Nichetti F, Corti F, Garcia MA, Iacovelli NA, Fallai C, de Braud F, Platania M, Del Vecchio M. *Oncol Res Treat* 2019; 42(4):186-194. doi: 10.1159/000497211.

"Exploiting metformin plus/minus cyclic Fasting Mimicking diet (FMD) to improve the efficacy of platinum-pemetrexed chemotherapy in advanced LKB1-inactivated lung adenocarcinoma: the FAME trial." Vernieri C, Signorelli D, **Galli G**, Ganzinelli M, Moro M, Fabbri A, Tamborini A, Marabese M, Caiola E, Brogini M, Hollander L, Gallucci R, Vandoni G, Gavazzi C, Triulzi T, Colombo MP, Rizzo AM, Corsetto P, Pruneri G, de Braud F, Sozzi G, Torri V, Garassino MC. *Clin Lung Can* 2018; 20(3):e413-e417. doi: 10.1016/j.clc.2018.12.011.

"MicroRNAs for the diagnosis and management of malignant pleural mesothelioma: a literature review." Palmieri D, Lo Russo G, Tessari A, Capece M, **Galli G**, de Braud F, Garassino MC. *Front Oncol* 2018 ; 8:650. doi: 10.3389/fonc.2018.00650.

"Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors." Fucà G, **Galli G**, Poggi M, Lo Russo G, Proto C, Imbimbo M, Ferrara R, Zilembo N, Ganzinelli M, Sica A, Torri V, Colombo MP, Vernieri C, Balsari A, de Braud F, Garassino MC, Signorelli D. *Esmo Open* 2018; 4:e000457. doi: 10.1136/esmoopen-2018-000457.

"Low baseline serum sodium concentration is associated with poor clinical outcomes in metastatic Non-Small Cell Lung Cancer patients treated with immunotherapy." Fucà G, **Galli G**, Poggi M, Lo Russo G, Proto C, Imbimbo M, Vitali M, Ganzinelli M, Lanti C, Molino G, Stangoni F, Zilembo N, de Braud F, Garassino MC, Signorelli D. *Targ Oncol* 2018; 13(6):795-800. doi: 10.1007/s11523-018-0599-5.

"Best practices for the management of thymic epithelial tumors: a position paper by the Italian collaborative group for ThYmic Malignancies (TYME)." Imbimbo M, Ottaviano M, Vitali M, Fabbri A, Leuzzi G, Fiore M, Franceschini D, Pasello G, Perrino M, Schiavoni M, Pruneri G, Dei Tos AP, Sangalli C, Garassino MC, Berardi R, Alessi A, Calareso G, Petrini I, Scorcorsetti M, Scotti V, Rosso L, Rea F, Pastorino U, Casali PG, Ramella S, Ricardi U, Abate-Daga L, Torri V, Trama A, Palmieri G, Marinoux M, Zucali PA, TYME network collaborators (Alloisio M, Apolone G, Ardizzoni A, Benvenuti M, Berruti A, Breda C, Buzzoni C, Calabrese F, Caraceni A, Cardillo G, Casadio C, Cassi E, Caterino M, Cecere FL, Chiti A, Crippa A, Curcio C, de Braud F, De Pas T, Di Tommaso L, Evoli A, Facciolo F, **Galli G**, Lopez I, Lo Russo G, Spinelli L, Luzzi L, Mantovani C, Marchianò A, Margaritora S, Monaco R, Morandi U, Novellino L, Piras MT, Porcu L, Priola A, Proto C, Ratto GB, Rena O, Rinaldi S, Roca E, Rocco G, Ruffini E, Signorelli D, Solli P, Spaggiari L, Stefani A, Veltri A, Vespro V, Zilembo N. *Can Treat Rev* 2018; 71:76-87. doi: 10.1016/j.ctrv.2018.10.001.

"Single Institution trial of anthracycline- and taxane-based chemotherapy for operable breast cancer: the ASTER study." Mariani G, **Galli G**, Cavalieri S, Valagussa P, Bianchi GV, Capri G, Cresta S, Ferrari L, Damian S, Duca M, de Braud F, Moliterni A. *The Breast J* 2018; 25(2):273-242. doi: 10.1111/tbj.13197.

"Vitamin D in melanoma: controversies and potential role in combination with immune check-point inhibitors." Stucci LS, D'Oronzo S, Tucci M, Macerollo A, Ribero S, Spagnolo F, Marra E, Picasso V, Orgiano L, Marconcini R, De Rosa F, Di Guardo L, **Galli G**, Gandini S, Palmieri G, Queirolo P, Silvestris F. *Can Treat Rev* 2018; 69:21-28. doi: 10.1016/j.ctrv.2018.05.016.

"The evolving landscape of criteria for evaluating tumor response in the era of cancer immunotherapy: From Kamofsky to iRECIST." Inno A, Lo Russo G, Salgarello M, Corrao G, Casolino R, **Galli G**, Modena A, Romano L, Pusceddu S, Greco FG, Garassino MC, Gori S. *Tumori* 2018; 104(2):88-95. doi: 10.1177/0300891618766173.

"Uncommon mutations in epidermal growth factor receptor and response to first and second generation tyrosine kinase inhibitors: a case series and literature review." **Galli G**, Corrao G, Imbimbo M, Proto C, Signorelli D, Ganzinelli M, Zilembo N, Vitali M, de Braud F, Garassino MC, Lo Russo G.

Lung Can 2018; 115:135-142. doi: 10.1177/0300891618766173.

"The use of breast imaging for predicting response to neoadjuvant lapatinib, trastuzumab and their combination in HER2 positive breast cancer: results from Neo-ALTTO." Di Cosimo S, Campbell C, Azim Jr HA, Galli G, Bregni G, Curigliano G, Criscitiello C, Izquierdo M, de la Pena L, Fumagalli D, Fein L, Vinholes J, NG WMJ, Colleoni M, Ferro A, Naume BJ, Patel A, Huober J, Piccart-Gebhart MJ, Baselga J and de Azambuja E. *Eur J Can* 2018; 89:42-48. doi: 10.1177/0300891618766173.

"Clinical implications for pro-GRP in small cell lung cancer. A single center experience." Cavalieri S, Morelli D, Martinetti A, Galli G, Nichetti F, de Braud F, Platania M. *Int J Biol Markers* 2017; 33(1):55-61. doi: 10.5301/ijbm.5000305.

"Neoadjuvant chemotherapy exerts selection pressure towards luminal phenotype breast cancer." Galli G, Bregni G, Cavalieri S, Porcu L, Baili P, Hade A, Di Salvo F, Sant M, Agresti R, Gennaro M, Folli S, De Santis MC, Paolini B, Carcangiu ML, de Braud F, Di Cosimo S. *Breast Care* 2017;12:391-394. doi: 10.1159/000479582.

"Disease-free interval in metastatic breast cancer patients undergoing complete remission: implications of cross-sectional study design and biologic considerations about disease history." Galli G, Tessari A, Di Cosimo S. *Breast Cancer* 2017; 24(3):491-492. doi: 10.1007/s12282-017-0766-z.

"Complete remission in metastatic breast cancer: expecting the unexpected - Results of a cross-sectional study." Galli G, Tessari A, Porcu L, Bregni G, Paolini B, Carcangiu ML, Gennaro M, De Sanctis MC, Lozza L, de Braud F, Di Cosimo S. *Breast Cancer* 2017; 24(4):635-641. doi: 10.1007/s12282-017-0751-6.

"HER2-positive neuroendocrine breast cancer: case report and review of literature." Gevorgyan A, Bregni G, Galli G, Zanardi E, de Braud F, Di Cosimo S. *Breast Care* 2016; 11:424-426. doi: 10.1159/000453572.

"Body mass index and clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer." Gevorgyan A, Bregni G, Galli G, Ganzinelli M, Martinetti A, Lo Vullo S, Mariani L, Festinese F, Sottotetti E, de Braud F, Di Cosimo S. *Tumori* 2016; 102(4):e11-14. doi: 10.5301/tj.5000515.

"Trastuzumab cardiac toxicity: a problem we put our heart into." Bregni G, Galli G, Gevorgyan A, de Braud F, Di Cosimo S. *Tumori* 2016;102(1):1-5. doi: 10.5301/tj.5000393.

"TOKIO rationale and protocol: a phase II study to evaluate the activity and safety of third-line tyrosine kinase inhibitor after 2 tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma." Verzoni E, Grassi P, Montone R, Galli G, Necchi A, Procopio G. *Tumori* 2015; 101(6):701-703. doi: 10.5301/tj.5000335.

"Disease progression pattern in metastatic breast cancer patients treated with anti-HER2 therapies." Serpico D, Porcu L, Tessari A, Gevorgyan A, Bregni G, Galli G, de Braud F, Torri V, Di Cosimo S. *Clin Transl Oncol* 2015; 17(7):530-538. doi: 10.1007/s12094-015-1274-2.

"Time from nephrectomy as a prognostic factor in metastatic renal cell carcinoma patients receiving targeted therapies: overall results from a large cohort of patients." Procopio G, Testa I, Verzoni E, Iacovelli R, Grassi P, Galli G, de Braud F, Saravia D, Salvioni R. *Oncology* 2015; 88(3):133-138. doi: 10.1159/000367809.

Pubblicazioni in formato abstract

"Accuracy of pathologic diagnosis of thymic epithelial tumors: a single Institution experience." Galli G, Fabbri A, Ferrara R, Prelaj A, Proto C, Signorelli D, De Toma A, Pagani F, Zilembo N, Ganzinelli M, Abate-Daga L, Pruneri G, de Braud F, Garassino M, Lo Russo G. [Accettato come poster ad AIOM 2019].

"Clinical characteristics and biological profile of Lung Enteric Adenocarcinoma." Imbimbo M, Galli G, Busico A, Perrone F, Tamborini E, Fabbri A, Marano G, Biganzoli D, Ferrara R, Lo Russo G, Prelaj A, Proto C, Zilembo N, De Toma A, Ganzinelli M, Biganzoli E, Pruneri G, de Braud F, Garassino MC, Signorelli D. [Accettato come poster ad AIOM 2019].

"Immune Checkpoint Inhibitors in the elderly with Non-Small Cell Lung Cancer: efficacy and safety." Randon G, De Toma A, Pagani F, Trevisan B, Prelaj A, Ferrara R, Proto C, Signorelli D, Ganzinelli M, Zilembo N, de Braud F, Garassino MC, Lo Russo G, Galli G. [Accettato come poster ad AIOM 2019].

"Accuracy of pathologic evaluation for thymic epithelial tumors in an Italian reference Centre." Galli G, Fabbri A, Ferrara R, Prelaj A, Proto C, Signorelli D, De Toma A, Pagani F, Zilembo N, Ganzinelli M, Abate-Daga L, Pruneri G, de Braud F, Garassino MC, Lo Russo G. *Ann Oncol* 2019; 30(suppl_5): v747-v755. 10.1093/annonc/mdz266 .

"Prognostic role of CD73 in metastatic Non Small Cell Lung Cancer according to the presence of driver alterations." Galli G, Ferrara R, Pagani F, De Toma A, Lo Russo G, Signorelli D, Prelaj A,

Zilembo N, Ganzinelli M, Brich S, Fabbri A, Sangaletti S, Pruneri G, Colombo M, de Braud F, Garassino MC, Proto C. *Ann Oncol* 2019; 30(suppl_5):v797-v815. 10.1093/annonc/mdz269.

"Efficacy and safety of immunotherapy in elderly patients with Non-Small Cell Lung Cancer." Galli G, De Toma A, Pagani F, Randon G, Trevisan B, Prelaj A, Ferrara R, Proto C, Signorelli S, Ganzinelli M, Zilembo N, de Braud F, Garassino MC, Lo Russo G. *J Thorac Oncol* 2019; 14(suppl 10):S454. <https://doi.org/10.1016/j.jtho.2019.08.941>.

"Clinical and biological characterization of Lung Enteric Adenocarcinoma." Galli G, Imbimbo M, Busico A, Perrone F, Tamborini E, Fabbri A, Marano G, Biganzoli D, Ferrara R, Lo Russo G, Prelaj A, Proto C, Zilembo N, De Toma A, Ganzinelli M, Biganzoli E, Pruneri G, de Braud F, Garassino MC, Signorelli D. *J Thorac Oncol* 2019; 14(suppl 10):S770. <https://doi.org/10.1016/j.jtho.2019.08.1654>.

"Impact of cholesterolemia and body mass index on outcome of metastatic Non Small Cell Lung Cancer treated with immunotherapy." Galli G, Corsetto PA, Ferrara R, Prelaj A, Proto C, Signorelli D, Zilembo N, De Toma A, Pagani F, Randon G, Ganzinelli M, Sica A, de Braud F, Garassino MC, Lo Russo G. *J Clin Oncol* 2019; 15 suppl: e20691. DOI: 10.1200/JCO.2019.37.15_suppl.e20691

"Immune-checkpoint inhibitors in metastatic Non Small Cell Lung Cancer with rare histology." Signorelli D, Ferrara R, Proto C, Lo Russo G, Imbimbo M, Galli G, De Toma A, Pagani F, Randon G, Fucà G, Trevisan B, Ganzinelli M, Zilembo N, Fabbri A, de Braud F, Garassino MC, Prelaj A. *J Clin Oncol* 2019; 15 suppl:9106. DOI: 10.1200/JCO.2019.37.15_suppl.9106.

"A plasma miRNA signature classifier identifies PD-L1≥50% NSCLC non responders to immune-checkpoint inhibitors." Proto C, Prelaj A, Verri C, Signorelli D, Lo Russo G, Ferrara R, Galli G, Trevisan B, Mavis M, de Braud F, Garassino MC, Sozzi G, Boeri M. *J Clin Oncol* 2019; 15 suppl:9096. DOI: 10.1200/JCO.2019.37.15_suppl.9096.

"Prognostic score for second or further line immunotherapy in advanced non-small-cell lung cancer (aNSCLC): an external validation." Prelaj A, Lo Russo G, Proto C, Signorelli D, Ferrara R, Galli G, De Toma A, Randon G, Zilembo N, Trevisan B, Montrone M, Longo V, Pesola F, Varesano N, Del Bene G, Pizzutilo P, Galetta D, Garassino MC, Di Maio M, Catino A. *J Clin Oncol* 2019; 15 suppl:14077. DOI: 10.1200/JCO.2019.37.15_suppl.14077.

"Characterization of patients with metastatic Non Small Cell Lung Cancer obtaining Long Term Benefit from Immunotherapy." Galli G, Proto C, Signorelli D, Imbimbo M, Ferrara R, Prelaj A, De Toma A, Randon G, Trevisan B, Ganzinelli M, Zilembo N, Garassino MC, Lo Russo G. *Ann Oncol* 2019; 30(suppl 2):ii56. <https://doi.org/10.1093/annonc/mdz063.048>.

"Metformin +/- cyclic fasting mimicking diet in combination with platinum-pemetrexed chemotherapy for advanced LKB1 inactive lung adenocarcinoma: the FAME trial." Galli G, Vemieri C, Signorelli D, Ganzinelli M, Moro M, Fabbri A, Tamborini E, Marabese M, Caiola E, Brogginini M, Hollander L, Gallucci R, Gavazzi C, Rizzo AM, Corsetto P, Pruneri G, de Braud F, Sozzi G, Torri V, Garassino MC. *Ann Oncol* 2019; 30(suppl 2):ii38-68. 10.1093/annonc/mdz063.

"EPSiLoN score: a predictive score using clinical and blood biomarkers in advanced non-small cell lung cancer (aNSCLC) patients treated with immunotherapy." Prelaj A, Lo Russo G, Signorelli D, Ferrara R, Imbimbo M, Galli G, De Toma A, Randon G, Brambilla M, Ganzinelli M, Zilembo N, de Braud F, Garassino MC, Proto C. [Accettato come poster ad ELCC 2019]. *Ann Oncol* 2019; 30(suppl 2):ii38-68. 10.1093/annonc/mdz063

"Is "hyper-progression" a relevant clinical item for patient with solid tumours candidate to check-point inhibitor treatment?" De Braud F, Di Nicola M, Damian S, Cresta S, Duca M, Indini A, Di Bartolomeo M, Galli G, Farè E, Verzoni E. *Ann Oncol* 2018; 29(suppl 3):ii5. DOI: 10.1093/annonc/mdy046.018.

"Concomitant immunotherapy and radiotherapy for metastatic non small cell lung cancer: a single Institution experience." Galli G, Botta L, Poggi M, Fucà G, Imbimbo M, Lo Russo G, Proto C, Vitali M, Zilembo N, Ganzinelli M, de Braud F, Garassino MC, Signorelli D. [Accettato come Poster ad AIOM 2018].

"Prognostic and predictive role of hyponatremia in patients with metastatic non-small cell lung cancer treated with immunotherapy." Fucà G, Poggi M, Galli G, Imbimbo M, Lo Russo G, Proto C, Signorelli D, Ganzinelli M, Zilembo N, de Braud F, Garassino MC, Vitali M. [Accettato come poster ad AIOM 2018].

"Basal lymphopenia as a potential predictor of benefit from immunotherapy in metastatic non small cell lung cancer." Galli G, Poggi M, Fucà G, Lo Russo G, Proto C, Signorelli D, Vitali M, Ganzinelli M, Zilembo N, de Braud F, Garassino M, Imbimbo M. *Ann Oncol* 2018; 29(suppl 8):viii493-viii547. 10.1093/annonc/mdy292.

"Effects of antibiotic use during immunotherapy in metastatic non small cell lung cancer ." Galli G, Poggi M, Fucà G, Imbimbo M, Proto C, Signorelli D, Vitali M, Zilembo N, Ganzinelli M, de Braud F,

Garassino M, Lo Russo G. *Ann Oncol* 2018; 29(suppl 8):mdy292.088. <https://doi.org/10.1093/annonc/mdy292.088>.

"Impact of early steroids use on clinical outcomes of patients with advanced NSCLC treated with immune checkpoint inhibitors." Fucà G, Poggi M, **Galli G**, Imbimbo M, Lo Russo G, Signorelli D, Vitali M, Ganzinelli M, Zilembo N, de Braud F, Garassino MC, Proto C. *Ann Oncol* 2018; 29(suppl 8):mdy292.012. <https://doi.org/10.1093/annonc/mdy292.012>.

"Management of CNS Mets in the Era of CNS-Penetrant TKIs (Med Onc and Rad Onco Perspectives)." **Galli G**, Garassino M. *J Thorac Oncol* 2018; 13(10 suppl):S290-S291. DOI: <https://doi.org/10.1016/j.jtho.2018.08.182>.

"Impact of antibiotics on outcome of metastatic non small cell lung cancer patients treated with immunotherapy." **Galli G**, Poggi M, Fucà G, Imbimbo M, Proto C, Signorelli D, Vitali M, Zilembo N, Ganzinelli M, de Braud F, Garassino M, Lo Russo G. *J Thorac Oncol* 2018; 13(10 suppl):S389. DOI: <https://doi.org/10.1016/j.jtho.2018.08.396>.

"Effect of early steroids use in advanced NSCLC patients treated with immunotherapy." Fucà G, Poggi M, **Galli G**, Imbimbo M, Lo Russo G, Proto C, Vitali M, Ganzinelli M, Zilembo N, de Braud F, Garassino MC, Signorelli D. *J Thoracic Oncol* 2018; 13(10 suppl):S390. DOI: <https://doi.org/10.1016/j.jtho.2018.08.398>.

"Effect of basal lymphopenia on outcome of non small cell lung cancer patients treated with immunotherapy." **Galli G**, Poggi M, Fucà G, Imbimbo M, Lo Russo G, Proto C, Signorelli D, Ganzinelli M, Zilembo N, de Braud F, Garassino M, Vitali M. *J Thoracic Oncol* 2018; 13(10 suppl):S468. DOI: <https://doi.org/10.1016/j.jtho.2018.08.578>.

"Prognostic value of the interval between the last neoadjuvant chemotherapy (CT) administration and breast surgery: Preliminary data of the NeoBracer international observational study." Cinausero M, **Galli G**, Basile D, Martorana F, De Santo I, Perroud HA, Zenovia Antone N, Campos Gomez S, Gerratana L, Minisini AM, Sant M, Folli S, Campos Gomez KA, Eniu AE, Cismaru A, Arpino G, Vigneri PG, Fasola G, Di Cosimo S, Puglisi F. *J Clin Oncol* 2018; 36(suppl; abstr e12629). DOI: 10.1200/JCO.2018.36.15_suppl.e12629.

"Combination of brain radiotherapy (RT) and immunotherapy (IT) in a single Institution cohort of patients (pts) with metastatic melanoma (MM)." **Galli G**, Cavalieri S, Di Guardo L, Cimminiello C, Corti F, Nichetti F, Garcia M, Tana S, Fallai C, de Braud F, Platania M, Del Vecchio M. *Ann Oncol* 2017; 28 (suppl 11):xi8. <https://doi.org/10.1093/annonc/mdx711.008>.

"TNM or tumor volume for predicting prognosis in malignant pleural mesothelioma: still an open debate." Imbimbo M, Proto C, Mallone S, Signorelli D, Greco FG, Calareso G, Botta L, Lo Russo G, Vitali M, Corrao G, **Galli G**, Ganzinelli M, Zilembo N, Pastorino U, Garassino MC, Trama A. *J Thorac Oncol* 2017; 12 (11, suppl 2):S2156–S2157.

"Brain radiotherapy (RT) and immunotherapy (IT) for metastatic melanoma (MM): a retrospective single Institution experience." **Galli G**, Cavalieri S, Di Guardo L, Cimminiello C, Corti F, Nichetti F, Garcia M, Tana S, Fallai C, de Braud F, Platania M, Del Vecchio M. *Ann Oncol* 2017; 28 (suppl 6):vi68. <https://doi.org/10.1093/annonc/mdx428.002>.

"Time to surgery after neoadjuvant chemotherapy for early breast cancer." Cinausero M, **Galli G**, Basile D, Gerratana L, Fasola G, de Braud F, Sant M, Paolini B, Puglisi B, Di Cosimo S. *Ann Oncol* 2017; 28 (suppl 6):vi29. <https://doi.org/10.1093/annonc/mdx424.014>.

"Long term results of ASTER study, a single Institution phase II trial of sequential chemotherapy (CT) for operable breast cancer (BC)." Mariani G, **Galli G**, Cavalieri S, Valagussa P, Bianchi G, Capri G, Cresta S, Ferrari L, Damian S, Duca M, de Braud F, Moliterni A. *Ann Oncol* 2017; 28 (suppl 6):vi34. <https://doi.org/10.1093/annonc/mdx424.033>.

"Profiling of peripheral blood T lymphocytes in solid tumor patients undergoing immune checkpoint blockade therapy." Tassi E, Grazia G, Vegetti C, Cimminiello C, Di Guardo L, Indini A, Galli G, Corrao G, Signorelli D, Proto C, Lo Russo G, Del Vecchio M, Garassino MC, Mortarini R, Anichini A. *EACR Conference Series - Defence is the Best Attack: Immuno-Oncology Breakthroughs Programme Book* 2017; p84.

"Time to surgery in early breast cancer treated with neoadjuvant chemotherapy." Cinausero M, **Galli G**, Basile D, Gerratana L, Fasola G, de Braud F, Sant M, Paolini B, Di Cosimo S, Puglisi F. *Ann Oncol* 2017; 28(suppl 5):iv49-50. 10.1093/annonc/mdx362.

"CAMLs and CTM in women treated for breast cancer: understanding the clinical value of circulating tumor associated cells." Di Cosimo S, Bottelli S, Reduzzi C, **Galli G**, Bregni G, Martinetti A, Paolini B, Verderio P, Cappelletti V. *EACR Proceedings Book* 2017; p143.

"Retrospective analysis of patients (pts) with metastatic melanoma (MM) showing long-term response

(LTR) to vemurafenib (Vb)." **Galli G**, Di Guardo L, Cimminiello C, Cavalieri S, Rodolfo M, Rivoltini L, Valeri B, Bono A, Tolomio E, Del Vecchio M. *J Clin Oncol* 2017; 35(suppl 13). DOI: 10.1200/JCO.2017.35.15_suppl.e21001.

"Ki67, tumor stage (TS) and axillary node metastases (ANMs): a complex relationship." **Galli G**, Bregni G, Meneghini E, Cavalieri S, Di Salvo F, Amash H, Paolini B, de Braud F, De Santis MC, Sant M, Di Cosimo S. *Ann Oncol* 2016; 27(suppl 4):iv59. <https://doi.org/10.1093/annonc/mdw337.02>.

"It's not the quality but the quantity: tumor mutation spectrum and response to neoadjuvant therapy in triple negative breast cancer." Di Cosimo S, Dugo M, Appierto V, Cavalieri S, Angeloni V, **Galli G**, Bregni G, Cappelletti V, Paolini B, Perrone E, Tiberio P, de Braud F. *Ann Oncol* 2016; 27(suppl 4):iv70. <https://doi.org/10.1093/annonc/mdw337.36>.

"Pro-gastrin releasing peptide (pro-GRP) in small cell lung cancer staging." Cavalieri S, Raimondi A, Morelli D, Martinetti A, de Braud F, Agustoni F, Dotti K, **Galli G**, Vernieri C, Fucà G, Peverelli G, Prisciandaro M, Nichetti F, Indelicato P, Lo Russo G, Prinzi N, Garassino M, Platania M. *Ann Oncol* 2016; 27(suppl 4):iv13. <https://doi.org/10.1093/annonc/mdw332.34>.

"Breast cancer, Ki67, tumor size and axillary nodes relationship: it's complicated." Bregni G, Meneghini E, **Galli G**, Cavalieri S, Di Salvo F, Amash H, Paolini B, de Braud F, De Santis MC, Sant M, Di Cosimo S. *Ann Oncol* 2016; 27(suppl 6):163P. <https://doi.org/10.1093/annonc/mdw364.19>.

"Effect of body mass index (BMI) on response to neoadjuvant therapy in human epidermal growth factor receptor 2 (HER2) positive breast cancer (BC): analysis from NeoALLTO trial." **Galli G**, Bradbury I, Cinieri S, Agbor-Tahr D, de Braud F, Baselga J, Huober J, Furnagalli D, Sarp S, Piccart M, de Azambuja E, Di Cosimo S. *Ann Oncol* 2016; 27(suppl 6):191P. <https://doi.org/10.1093/annonc/mdw364.47>.

"Neo-adjuvant chemotherapy for the treatment of breast cancer exerts a selection pressure toward luminal phenotype." **Galli G**, Porcu L, Baii P, Amash H, Di Salvo F, Bregni G, Agresti R, Gennaro M, De Santis MC, Ferrari B, de Braud F, Di Cosimo S. *Canc Res* 2016; 76 (suppl 4):P114-P122.

"Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer according to body mass index." Gevorgyan A, Ganzinelli M, Martinetti A, Lo Vullo S, Mariani L, Festinese F, Sottotetti E, Ferrari B, **Galli G**, de Braud F, Di Cosimo S. *Ann Oncol* 2015; 26(suppl 6):vi12-vi13. <https://doi.org/10.1093/annonc/mdv336.31>.

"First analysis of ASTER study AT for 3 cycles followed by CMF for 3 cycles as neo or adjuvant chemotherapy in early stage breast cancer. A single institution experience." Mariani G, **Galli G**, Mariani P, Bianchi GV, Capri G, Cresta S, De Benedictis E, Valagussa P, Magazzù D, de Braud F, Moliterni A. *Canc Res* 2013; 73(suppl 24):P312-P313.

Partecipazione a congressi
in qualità di relatrice

I Tumori Epiteliali del Timo: stato dell'arte e prospettive future – Milano, 29/11/2019

World Congress on Lung Cancer 2018 – Toronto, 24-26/09/2018

Grandangolo in Oncologia: Focus su terapie di supporto 2017 – Bologna, 8-9 maggio 2017

Skin Cancer Master su "Ottimizzazione del trattamento multidisciplinare nel melanoma metastatico e nel basalioma avanzato" - Milano, 21-22/11/2016

Congresso Nazionale dell'Associazione Italiana di Oncologia Medica - Roma, 28-30/10/2016

Autorizzazione al trattamento
dei dati personali

Autorizzo il trattamento dei miei dati personali ai sensi dell'art. 13 d. lgs. 30 giugno 2003 n°196 – "Codice in materia di protezione dei dati personali" e dell'art. 13 GDPR 679/16 – "Regolamento europeo sulla protezione dei dati personali"



